BHV-5000

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameBHV-5000
Drug Alias NameProdrug of lanicemineBHV-5000
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsRett Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceutical Co LtdBiohaven Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsRett Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A